Payment overview · 2025
General Payments
$794.48
45 reported records · 15 companies
Healthcare provider profile · identity verified
Steven M Koerth, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ATHENS, TX · NPI 1124023130
Verified facts
What the public records show
CMS Open Payments records show Steven M Koerth, M.D. received $794.48 in general payments during 2025 across 45 reported records.
Novo Nordisk Inc accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.73 | 21.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.41 | 18.4% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $90.24 | 11.4% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $58.36 | 7.3% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $55.46 | 7.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.56 | 6.5% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $47.16 | 5.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.77 | 5.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.76 | 4.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.54 | 2.7% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $17.84 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.29 | 1.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.94 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.86 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.48 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $146.41 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.41 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $144.99 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.24 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.81 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $55.46 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $47.16 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 221 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 209 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
221 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
221 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
209 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1071 | 288 |
| Pantoprazole Sodium | Pantoprazole Sodium | 723 | 196 |
| Lisinopril | Lisinopril | 649 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 131 |
| Sertraline Hcl | Sertraline Hcl | 451 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 387 | 109 |
| Losartan Potassium | Losartan Potassium | 384 | 108 |
| Omeprazole | Omeprazole | 345 | 100 |
| Potassium Chloride | Potassium Chloride | 342 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 85 |
| Famotidine | Famotidine | 335 | 119 |
| Gabapentin | Gabapentin | 326 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 103 |
| Furosemide | Furosemide | 323 | 102 |
| Allopurinol | Allopurinol | 307 | 83 |
| Metformin Hcl | Metformin Hcl | 289 | 78 |
| Alendronate Sodium | Alendronate Sodium | 270 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 247 | 67 |
| Montelukast Sodium | Montelukast Sodium | 233 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 230 | 94 |
| Simvastatin | Simvastatin | 226 | 63 |
| Celecoxib | Celecoxib | 224 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 223 | 60 |
| Jardiance | Empagliflozin | 221 | 48 |
| Prednisone | Prednisone | 220 | 160 |
| Ozempic | Semaglutide | 209 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 84 |
| Carvedilol | Carvedilol | 205 | 50 |
| Meloxicam | Meloxicam | 201 | 64 |
| Trazodone Hcl | Trazodone Hcl | 195 | 55 |
| Glimepiride | Glimepiride | 176 | 43 |
| Eliquis | Apixaban | 167 | 40 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 160 | 121 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 40 |
| Donepezil Hcl | Donepezil Hcl | 145 | 29 |
| Atenolol | Atenolol | 129 | 32 |
| Spironolactone | Spironolactone | 115 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 26 |
| Finasteride | Finasteride | 107 | 30 |
| Mupirocin | Mupirocin | 104 | 77 |
| Ezetimibe | Ezetimibe | 103 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 102 | 23 |
| Warfarin Sodium | Warfarin Sodium | 102 | 22 |
| Xarelto | Rivaroxaban | 96 | 20 |
| Metformin Hcl Er | Metformin Hcl | 95 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 31 |
| Methocarbamol | Methocarbamol | 84 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 14 |
| Divalproex Sodium | Divalproex Sodium | 82 | 12 |
| Azithromycin | Azithromycin | 81 | 70 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Cefdinir | Cefdinir | 73 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 20 |
| Amoxicillin | Amoxicillin | 71 | 65 |
| Mirtazapine | Mirtazapine | 71 | 11 |
| Levetiracetam | Levetiracetam | 69 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 58 |
| Azelastine Hcl | Azelastine Hcl | 66 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Memantine Hcl | Memantine Hcl | 63 | 18 |
| Glipizide | Glipizide | 61 | 12 |
| Buspirone Hcl | Buspirone Hcl | 60 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 16 |
| Lovastatin | Lovastatin | 57 | 12 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Bupropion Xl | Bupropion Hcl | 55 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Sotalol | Sotalol Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 21 |
| Folic Acid | Folic Acid | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 28 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 13 |
| Fluconazole | Fluconazole | 33 | 22 |
| Nitroglycerin | Nitroglycerin | 31 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Felodipine Er | Felodipine | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 15 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Nystop | Nystatin | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 18 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 14 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 14 |
| Valsartan | Valsartan | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.48 · 45 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, ECC Solutions, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, VOQUEZNA, Wegovy, XYOSTED, ZORYVE, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error